ÂÜÀòÂÒÂ×

Ron Gansevoort, professor of Medicine and nephrologist, works at the Dept. of Nephrology at the University Medical Center Groningen, the Netherlands. He has two lines of research: the epidemiology of chronic kidney disease (CKD) and the prevention of renal function loss in patients with heritable polycystic kidney disease (PKD). He is the coordinator of the PREVEND study, an observational general population-based study, investigating the association between albuminuria and health outcomes, and a member of the Steering Committee of the international CKD Prognosis Consortium. He was instrumental in the work that led to the new KDIGO classification of CKD, for which he was awarded the United States Kidney Foundation Distinguished International Medal. Prof. Gansevoort also is the head of the Groningen Expertise Centre for PKD. He was/is a member of the Steering Committee of several international randomized controlled clinical trials in the field of PKD (TEMPO 3:4, TEMPO 4:4, REPRISE, DIPAK-1, STAGED-PKD), as well as diabetic nephropathy (ARTS-DN, FIDELIO, FIGARO). Prof. Gansevoort is an associate editor for 5 international nephrological journals, published over 500 peer-reviewed papers, and supervised over 20 Ph.D. theses.